LLY

1,008.98

-0.15%↓

JNJ

201.79

-0.2%↓

ABBV

226.23

-1.07%↓

UNH

330.51

-0.85%↓

AZN

90.18

+0.23%↑

LLY

1,008.98

-0.15%↓

JNJ

201.79

-0.2%↓

ABBV

226.23

-1.07%↓

UNH

330.51

-0.85%↓

AZN

90.18

+0.23%↑

LLY

1,008.98

-0.15%↓

JNJ

201.79

-0.2%↓

ABBV

226.23

-1.07%↓

UNH

330.51

-0.85%↓

AZN

90.18

+0.23%↑

LLY

1,008.98

-0.15%↓

JNJ

201.79

-0.2%↓

ABBV

226.23

-1.07%↓

UNH

330.51

-0.85%↓

AZN

90.18

+0.23%↑

LLY

1,008.98

-0.15%↓

JNJ

201.79

-0.2%↓

ABBV

226.23

-1.07%↓

UNH

330.51

-0.85%↓

AZN

90.18

+0.23%↑

Kodu・Aktsiate loetelu・REVOLUTION Medicines Inc

REVOLUTION Medicines Inc

Suletud

SektorTervishoid

79.69 1.98

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

77.67

Max

79.79

Põhinäitajad
By Trading Economics
Sissetulek	-57M -305M
Kasumimarginaal	-74.379
Töötajad	809
EBITDA	-41M -302M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+1.87% upside

Turustatistika
By TradingEconomics
Turukapital	3.6B 15B
Eelmine avamishind	77.71
Eelmine sulgemishind	79.69

Uudiste sentiment

By Acuity

11%

89%

9 / 374 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Strong Bullish Evidence

40.67 / 41.96 Toetus ja vastupanu

REVOLUTION Medicines Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

17. okt 2025, 18:13 UTC

Suurimad hinnamuutused turgudel

Revolution Medicines Rises as FDA Grants Priority Designation for Cancer Treatment

Võrdlus sarnastega

Hinnamuutus

REVOLUTION Medicines Inc Prognoos

Hinnasiht

By TipRanks

1.87% tõus

12 kuu keskmine prognoos

Keskmine 79.95 USD 1.87%

Kõrge 104 USD

Madal 67 USD

Põhineb 20 Wall Streeti analüütiku instrumendi REVOLUTION Medicines Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

20 ratings

Osta

Hoia

Müü

Põhineb 20 analüütiku instrumendi REVOLUTION Medicines Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

40.67 / 41.96Toetus ja vastupanu

Recent bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

Sentiment

By Acuity

9 / 374 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest REVOLUTION Medicines Inc

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.